Cardiovascular disease (CVD) remains one of the world’s most pressing health challenges, affecting millions of people and their families worldwide. For patients living with CVD - and for those at risk - the threat of heart attack or stroke is a constant and deeply personal concern. With millions of lives lost to cardiovascular disease each year, the need for effective, evidence‑based solutions has never been greater.

At Amarin, we believe patients, their loved ones, and society as a whole deserve access to reliable cardiovascular health management options and proven treatments. People around the world -today and in the future -depend on companies like ours to help address this burden. We see this as both a responsibility and an opportunity: to help improve cardiovascular outcomes and change lives for the better.

While major behavioral risk factors such as tobacco use, unhealthy diet, physical inactivity, and harmful alcohol use contribute significantly to cardiovascular disease, many patients remain at risk even with appropriate lifestyle changes and standard interventions. In particular, despite achieving recommended LDL‑C targets, millions of patients continue to face a persistent risk of cardiovascular events - especially those with elevated and high triglycerides. ¹

This ongoing unmet need is why science is at the heart of everything we do. Our ambition is to be part of the solution by advancing evidence‑based cardiovascular treatments that support patients and clinicians in addressing residual cardiovascular risk.